KN has received honoraria from AstraZeneca, Bayer, Boehringer Ingelheim Japan, Daiichi Sankyo, Eli Lilly Japan, Kowa, Mitsubishi Tanabe, MSD, Novartis, Novo Nordisk, and Otsuka
Many alternatives, particularly GLP-1 agonists like Wegovy, Saxenda, and Zepbound, share similar side effects with Ozempic
Both Novo Nordisk and Eli Lilly face significant challenges in scaling up production to meet this demand
For example, if you are 10 pounds overweight, that equates to 40 extra pounds of pressure that is applied to the knees
Programs that ignore the impact of GLP-1s risk missing out on growth opportunities in this area
For erectile dysfunction medication, you must provide a blood pressure measurement from within the last six months